I agree that this site is using cookies. You can find further informations here.
X
Barrientos, JC
30  results:
Search for persons X
?
1

PCR123 Patient-Reported Outcomes (PROs) From the informCLL ..:

Sharman, J ; Barrientos, JC ; Ghosh, N...
Value in Health.  25 (2022)  7 - p. S564 , 2022
Link: https://doi.org/10.1016/..
 
?
2

ESTRATEGIAS DE AFRONTAMIENTO Y AJUSTE SOCIOEMOCIONAL EN CON..:

Barrientos, J-C. ; Arroyo-Vargas, P. ; Singuri-Pacara, D..
Revista de Salud Pública.  , 2017
Link: https://doi.org/10.31052..
 
?
3

Hairy cell leukemia and COVID-19 adaptation of treatment gu..:

Grever, M ; Andritsos, L ; Banerji, V...
issn:0887-6924.  , 2021
Link: http://hdl.handle.net/11..
 
?
4

Oral PI3K-δ,γ Inhibitor for the Management of People with C..:

Shah A ; Barrientos JC
https://www.dovepress.com/oral-pi3k-deltagamma-inhibitor-for-the-management-of-people-with-chron-peer-reviewed-article-OTT.  , 2021
Link: https://doaj.org/article..
 
?
5

No increased bleeding events in patients with relapsed chro..:

Barrientos, JC ; Hillmen, P ; Salles, G...
https://eprints.whiterose.ac.uk/170209/6/No%20increased%20bleeding%20events%20in%20patients%20with%20relapsed%20chronic%20lymphocytic%20leukemia%20and%20indolent%20non%20Hodgkin%20lymphoma%20treated%20with%20idelalisib.pdf.  , 2020
Link: https://eprints.whiteros..
 
?
6

Outcomes with ibrutinib by line of therapy and post‐ibrutin..:

O'Brien, SM ; Byrd, JC ; Hillmen, P...
https://eprints.whiterose.ac.uk/157136/1/O%27Brien_et_al-2019-American_Journal_of_Hematology.pdf.  , 2019
Link: https://eprints.whiteros..
 
?
7

Final analysis from RESONATE: Up to six years of follow-up ..:

Munir, T ; Brown, JR ; O'Brien, S...
issn:0361-8609.  , 2019
Link: http://hdl.handle.net/11..
 
?
8

Characterizing the kinetics of lymphocytosis in patients wi..:

Barrientos, JC ; Burger, JA ; Byrd, JC...
https://eprints.whiterose.ac.uk/140596/9/08_05_2019_Characteri.pdf.  , 2019
Link: https://eprints.whiteros..
 
?
9

Final analysis from RESONATE: Up to six years of follow‐up ..:

Munir, T ; Brown, JR ; O'Brien, S...
https://eprints.whiterose.ac.uk/157229/1/Munir_et_al-2019-American_Journal_of_Hematology.pdf.  , 2019
Link: https://eprints.whiteros..
 
?
10

Extended follow-up and impact of high-risk prognostic facto..:

Brown, JR ; Hillmen, P ; O'Brien, S...
https://eprints.whiterose.ac.uk/118291/10/leu2017175.pdf.  , 2018
Link: https://eprints.whiteros..
 
?
11

Improvement in Parameters of Hematologic and Immunologic Fu..:

Barrientos, JC ; O'Brien, S ; Brown, JR...
issn:2152-2650.  , 2018
Link: http://hdl.handle.net/11..
 
?
12

Extended follow-up and impact of high-risk prognostic facto..:

Brown, JR ; Hillmen, P ; O'Brien, S...
issn:0887-6924.  , 2018
Link: http://hdl.handle.net/11..
 
?
13

Improvement in Parameters of Hematologic and Immunologic Fu..:

Barrientos, JC ; O'Brien, S ; Brown, JR...
https://eprints.whiterose.ac.uk/140599/3/1-s2.0-S2152265018305743-main.pdf.  , 2018
Link: https://eprints.whiteros..
 
?
14

Extended follow-up and impact of high-risk prognostic facto..:

Brown, JR ; Hillmen, P ; O'Brien, S...
qt9q42p90f.  , 2018
Link: https://escholarship.org..
 
?
15

Ibrutinib in previously treated chronic lymphocytic leukemi..:

Montillo, M ; O'Brien, S ; Tedeschi, A...
qt1w2179mv.  , 2017
Link: https://escholarship.org..
 
1-15